Christopher Ryan Sullivan - Aug 13, 2024 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Financial Officer
Signature
/s/ Donald R. Reynolds, by Power of Attorney
Stock symbol
AVTX
Transactions as of
Aug 13, 2024
Transactions value $
$0
Form type
4
Date filed
8/14/2024, 04:11 PM
Previous filing
Jun 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AVTX Common Stock 6 Aug 13, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +187K $0.00 187K Aug 13, 2024 Common Stock 187K $9.88 Direct F1
transaction AVTX Restricted Stock Units Award $0 +72.6K $0.00 72.6K Aug 13, 2024 Common Stock 72.6K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock upon the vesting date.
F3 The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.

Remarks:

The amount of beneficial securities owned in Table I has been adjusted to reflect a 1-for-240 reverse stock split on December 28, 2023.